JS012 / Shanghai Junshi Biosci - LARVOL DELTA

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | N=204 ➔ 3 | Trial completion date: Nov 2025 ➔ Sep 2022 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2025 ➔ Sep 2022; Due to the adjustment and change of the sponsor's R&D strategy, we now plan to voluntarily terminate this clinical trial.

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=204 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P1 trial • Oncology • Solid Tumor